BR112012010502A2 - derivados de benzimidazol-imidazol - Google Patents

derivados de benzimidazol-imidazol

Info

Publication number
BR112012010502A2
BR112012010502A2 BR112012010502A BR112012010502A BR112012010502A2 BR 112012010502 A2 BR112012010502 A2 BR 112012010502A2 BR 112012010502 A BR112012010502 A BR 112012010502A BR 112012010502 A BR112012010502 A BR 112012010502A BR 112012010502 A2 BR112012010502 A2 BR 112012010502A2
Authority
BR
Brazil
Prior art keywords
imidazole derivatives
benzimidazole imidazole
benzimidazole
derivatives
imidazole
Prior art date
Application number
BR112012010502A
Other languages
English (en)
Inventor
Ioannis Nicolaos Houpis
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
Stefaan Julien Last
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of BR112012010502A2 publication Critical patent/BR112012010502A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012010502A 2009-11-04 2010-11-03 derivados de benzimidazol-imidazol BR112012010502A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09175015 2009-11-04
EP10154583 2010-02-24
PCT/EP2010/066668 WO2011054834A1 (en) 2009-11-04 2010-11-03 Benzimidazole-imidazole derivatives

Publications (1)

Publication Number Publication Date
BR112012010502A2 true BR112012010502A2 (pt) 2016-03-15

Family

ID=43266424

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010502A BR112012010502A2 (pt) 2009-11-04 2010-11-03 derivados de benzimidazol-imidazol

Country Status (22)

Country Link
US (3) US9427428B2 (pt)
EP (1) EP2496572A1 (pt)
JP (1) JP6005515B2 (pt)
KR (1) KR20120091292A (pt)
CN (1) CN102741241B (pt)
AP (1) AP2012006216A0 (pt)
AR (1) AR078888A1 (pt)
AU (1) AU2010317085A1 (pt)
BR (1) BR112012010502A2 (pt)
CA (1) CA2780034C (pt)
CL (1) CL2012001176A1 (pt)
CO (1) CO6531445A2 (pt)
CR (1) CR20120302A (pt)
EA (1) EA022839B1 (pt)
EC (1) ECSP12011867A (pt)
IL (1) IL219087A0 (pt)
MX (1) MX2012005178A (pt)
TW (1) TW201127378A (pt)
UA (1) UA108211C2 (pt)
UY (1) UY32997A (pt)
WO (1) WO2011054834A1 (pt)
ZA (1) ZA201203205B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150939A1 (es) 2008-12-03 2015-07-19 Presidio Pharmaceuticals Inc Inhibidores de la proteina no estructural 5a del virus de la hepatitis c
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2753382C (en) * 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
RS54386B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
SG188957A1 (en) 2010-01-25 2013-05-31 Enanta Pharm Inc Hepatitis c virus inhibitors
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CA2800509A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2014514295A (ja) * 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EA026667B9 (ru) 2011-09-16 2017-07-31 Джилид Фармассет Ллс Фармацевтическая композиция для лечения вируса гепатита с
ES2601461T3 (es) * 2011-12-28 2017-02-15 Janssen Sciences Ireland Uc Derivados de quinazolinona como inhibidores de VHC
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2864342A1 (en) * 2012-02-13 2013-08-22 Presidio Pharmaceuticals, Inc. Solid forms comprising inhibitors of hcv ns5a, compositions thereof, and uses therewith
CN102796084A (zh) * 2012-09-10 2012-11-28 合肥科尚医药科技有限公司 一种活性物质及其在治疗丙型肝炎中的应用及制备方法
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015187818A1 (en) * 2014-06-03 2015-12-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
AU2022279234A1 (en) 2021-05-21 2023-12-07 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
CN116462622B (zh) * 2023-03-10 2024-02-09 上海药坦药物研究开发有限公司 一种N-Boc-L-脯氨醛的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4213765A (en) 1979-01-02 1980-07-22 Union Carbide Corporation Oxidative coal desulfurization using lime to regenerate alkali metal hydroxide from reaction product
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
WO1997040028A1 (en) 1996-04-23 1997-10-30 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
JP4184610B2 (ja) 1999-03-19 2008-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｍｐｄｈ酵素のインヒビター
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2003298839A1 (en) * 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AP2009004840A0 (en) 2006-10-13 2009-04-30 Xtl Biopharmaceuticals Ltd Compounds and methods for treatment of HCV
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
AU2008350327B2 (en) 2008-02-12 2013-09-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SI2242752T1 (sl) 2008-02-13 2013-03-29 Bristol-Myers Squibb Company Imidazolil bifnil imidazoli kot hepatitis c virusni inhibitorji
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9120779B2 (en) * 2008-12-03 2015-09-01 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
PE20150939A1 (es) * 2008-12-03 2015-07-19 Presidio Pharmaceuticals Inc Inhibidores de la proteina no estructural 5a del virus de la hepatitis c
WO2010064139A2 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010096777A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
CA2753382C (en) * 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
RS54386B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
WO2010138791A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c

Also Published As

Publication number Publication date
EA022839B1 (ru) 2016-03-31
US20140107172A1 (en) 2014-04-17
AR078888A1 (es) 2011-12-07
US20160340344A1 (en) 2016-11-24
ECSP12011867A (es) 2012-10-30
TW201127378A (en) 2011-08-16
JP6005515B2 (ja) 2016-10-12
IL219087A0 (en) 2012-06-28
AU2010317085A1 (en) 2012-05-10
KR20120091292A (ko) 2012-08-17
CA2780034A1 (en) 2011-05-12
CN102741241B (zh) 2015-05-20
EP2496572A1 (en) 2012-09-12
US9427428B2 (en) 2016-08-30
UA108211C2 (uk) 2015-04-10
WO2011054834A1 (en) 2011-05-12
EA201290260A1 (ru) 2013-12-30
CL2012001176A1 (es) 2012-08-31
ZA201203205B (en) 2014-10-29
MX2012005178A (es) 2012-06-08
US20120219594A1 (en) 2012-08-30
CA2780034C (en) 2018-04-10
CO6531445A2 (es) 2012-09-28
CR20120302A (es) 2012-10-25
UY32997A (es) 2011-05-31
AP2012006216A0 (en) 2012-04-30
US9433609B2 (en) 2016-09-06
JP2013510119A (ja) 2013-03-21
CN102741241A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
BR112012010502A2 (pt) derivados de benzimidazol-imidazol
LTC2170860I2 (lt) Benzimidazolo dariniai
BR112012004969A2 (pt) derivados de bis-benzimidazol
BR112012002662A2 (pt) derivados de bis-benzimidazol
BR112012015868A2 (pt) derivados de imidazolidinadiona
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI1008749A2 (pt) Derivados de benzodiazepina
ECSP12011999A (es) Derivados benzamida sustituidos
BR112013013914A2 (pt) derivados de hidantoína úteis como inibidores de kv3
DK2283904T3 (da) Komponentsystem
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI0817609A2 (pt) Derivados de imidazol
DK2397480T3 (da) Diazepindionderivat
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BR112013013695A2 (pt) derivado de pirazol
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
DK2275414T3 (da) Cyclopentylacrylamidderivat
BR112012016923A2 (pt) Derivados de pirazol
BRPI0818855A2 (pt) Derivados de imidazol
DK2387580T3 (da) Deoxyactagardinderivater
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI0907963A2 (pt) Derivados de indazola

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.